Relevant conflicts of interest/financial disclosures: Nothing to report.
Version of Record online: 13 SEP 2012
Copyright © 2012 Movement Disorder Society
Volume 27, Issue 11, pages 1373–1378, 15 September 2012
How to Cite
Fox, S. H., Johnston, T. H., Li, Q., Brotchie, J. and Bezard, E. (2012), A critique of available scales and presentation of the non-human primate dyskinesia rating scale. Mov. Disord., 27: 1373–1378. doi: 10.1002/mds.25133
Full financial disclosures and author roles may be found in the online version of this article.
- Issue online: 21 SEP 2012
- Version of Record online: 13 SEP 2012
- Manuscript Accepted: 12 JUL 2012
- Manuscript Revised: 26 JUN 2012
- Manuscript Received: 18 APR 2012
- Parkinson's disease;
Levodopa-induced dyskinesia (LID) is a major limitation of long-term management of Parkinson's disease. The roadblocks that have hindered the development of new treatments for levodopa-induced dyskinesia were discussed at a meeting organized by the Michael J. Fox Foundation for Parkinson's research (New York, NY, March 2011). Among these, the lack of consensus methodology and clinical applicability for eliciting and rating LID in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)–treated monkeys was highlighted as a particular concern. Here we present an update on the practical use of rating scales for evaluating LID in MPTP-lesioned primate models of PD, with a focus on macaques, and present specifics on the Non-Human Primate Dyskinesia Rating Scale. © 2012 Movement Disorder Society